A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

  • STATUS
    Recruiting
  • participants needed
    132
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 19 February 2024
cancer
breast cancer
lung cancer
skin cancer
dyspnea
diarrhea
gastrointestinal cancer
chest tightness
cough
systemic therapy
pharyngitis
covid-19
chills
SARS
nervous
hydroxychloroquine
sore throat
antigen test
cns tumor
serologic test
ache
anosmia
nervous system
throat
acute respiratory syndrome (sars)
prostate cancer
cns neoplasms

Summary

The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study drug and is taken in the same way, but it does not contain any active ingredients.

Details
Condition Cancer, Covid 19
Age 18years - 100years
Treatment Placebo, Hydroxychloroquine, Radiation Therapy
Clinical Study IdentifierNCT04381988
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18
ECOG 0-3
For patients who have not started radiation at the time of screening: patients are required to have a plan in place for a minimum of 10 radiation treatments with or without concurrent systemic therapy
For patients who have already started radiation at the time of screening: patients must complete enrollment such that they are able to receive at least 10 radiation treatments with hydroxychloroquine
Disease Site
Mandatory inclusion criteria
No COVID-19 symptoms within 14 days of enrollment
(Temp >38C in addition to sore throat, cough, wheezing, chest tightness, shortness of breath, body aches, chills, diarrhea, and anosmia)
If symptoms are present within 14 days of enrollment, patients with a negative COVID-19 PCR or COVID-19 serology assay are eligible for inclusion
No close contact with confirmed COVID-19 person
Close contact defined as
Within 6 feet for prolonged period
Cohabitating
Optional laboratory criteria (Recommended if available)
Negative pre-treatment SARS-CoV-2 rapid antigen test result (within 1 week of enrollment)
Negative pre-treatment SARS-CoV-2 PCR test result (within 1 week of enrollment) using MSKCC laboratory or outside laboratory assay
Negative pre-treatment Standard Q COVID-19 IgM/IgG rapid serology result (within 1 week of enrollment)
Blood serum for SARS-CoV-2 serology tests (being validated by MSKCC)
Disease site meets following criteria
Head and Neck / High-Risk Skin Cancer
Lung Cancer
Breast Cancer
Prostate Cancer
Central Nervous System Tumors
Gastrointestinal System Cancer
Gynecologic cancer
Other disease sites permitted at PI discretion

Exclusion Criteria

Previous positive test for SARS-CoV-2
Previous positive serology test for SARS-CoV-2
Recent Chest CT meeting CT exclusion criteria
Live in a skilled nursing facility with COVID-19 symptoms (Temp >38 C in addition to sore throat, cough, wheezing, chest tightness, shortness of breath, body aches or chills, diarrhea, anosmia)
Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives
Pre-existing retinopathy
Known chronic kidney disease, stage 4 or 5, or receiving dialysis
Breast Feeding
Tamoxifen
Absolute neutrophil Count <1,000/ml at registration
Concurrent use of any other quinine derivative
Antiarrhythmic medications: amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide
Glucose-6-phosphate dehydrogenase deficiency
Pre-treatment corrected QT interval (QTc) 470 milliseconds
Prisoners
Inability to participate
Psoriasis
History of suicidal ideation
CT Criteria for Enrollment Exclusion (Optional - only for patients who received a diagnostic CT as part of standard of care or a thoracic CT as part of radiation simulation): All patients with COVID-19 typical radiographic findings on CT Chest as defined by the RSNA will be excluded. Patients with any NEW COVID-19 indeterminate radiographic findings on CT Chest that are concerning for COVID-19 will be excluded. COVID-19 indeterminate features are permitted if they can be demonstrated as STABLE on prior (>14 calendar days) CT Chest or PET/CT. If no prior comparison is available AND any intermediate or typical feature is present, the patient is not eligible
COVID-19 Atypical Features
Isolated lobar or segmental consolidation without GGO
Discrete small nodules (centrilobular, "tree-in-bud")
Lung cavitation
Smooth interlobular septal thickening with pleural effusion
COVID-19 Indeterminate Features
Multifocal, diffuse, perihilar, or unilateral GGO with or without consolidation lacking a specific distribution and are non-rounded or non-peripheral
Few very small GGO with a non-rounded and non-peripheral distribution
COVID-19 Typical Features
Peripheral, bilateral GGO with or without consolidation or visible intralobular lines ("crazy paving")
Multifocal GGO of rounded morphology with or without consolidation or visible intralobular lines ("crazy paving")
Reverse Halo sign or other findings of organizing pneumonia If pre-treatment QTC can be decreased to <470, the patient can be re-considered for trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.